Amphastar Pharmaceuticals Inc vs Vanguard Value Index Fund ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Vanguard Value Index Fund ETF trades at $225.17. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VTV | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | — |
52-Week High | $30.81 | $225.35 |
52-Week Low | $16.87 | $179.43 |
Enterprise Value | $1.26B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
VTV trades at $224.31, up 0.42% today, with a bullish technical outlook supported by moving averages and near-term resistance at $225. The ETF has gained 22% year-to-date in 2026, outperforming growth-focused peers as value strategies attract attention amid flat market growth. A dividend of $1.08 is scheduled for June 2026.
The outlook remains positive given value's recent momentum and low exposure to tech volatility, but risks include Federal Reserve policy shifts and stretched RSI levels. Institutional activity is mixed, with some trimming positions while others increase stakes, reflecting cautious optimism.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →